NCT04550481View on ClinicalTrials.gov

Role of Lisinopril in Preventing the Progression of Non-Alcoholic Fatty Liver Disease, RELIEF-NAFLD Study

PHASE2Active, not recruitingINTERVENTIONAL
Enrollment

45

Participants

Timeline

Start Date

May 11, 2021

Primary Completion Date

October 31, 2025

Study Completion Date

September 30, 2026

Conditions
Hepatocellular CarcinomaNonalcoholic Steatohepatitis
Interventions
PROCEDURE

Biospecimen Collection

Undergo blood sample collection

DRUG

Lisinopril

Given PO

PROCEDURE

Liver Ultrasonographic Elastography

Undergo transient elastography

PROCEDURE

Magnetic Resonance Elastography

Undergo PDFF MRE

PROCEDURE

Magnetic Resonance Imaging

Undergo PDFF MRI

PROCEDURE

Proton Density Fat Fraction

Undergo PDFF MRI/MRE

OTHER

Questionnaire Administration

Ancillary studies

Trial Locations (4)

10029

Mount Sinai Hospital, New York

27710

Duke University Medical Center, Durham

55905

Mayo Clinic in Rochester, Rochester

90048

Cedars Sinai Medical Center, Los Angeles

All Listed Sponsors
collaborator

National Cancer Institute (NCI)

NIH

lead

Northwestern University

OTHER